top of page
Browse by category
Search
Semaglutide before bariatric surgery does not improve weight loss or safety, suggesting a ‘surgery-first strategy’ could lead to better outcomes
Total weight loss did not increase for patients who took semaglutide before having BMS, suggesting that a surgery-first strategy could...
Journal Watch 19/2/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Clinical trial confirms semaglutide reduces cravings for alcohol and heavy drinking
Semaglutide could also help people cut down on their alcohol intake, according to the findings from the ‘Human Laboratory Screening of...
Rani Therapeutics reveals data on semaglutide administered via the RaniPill capsule
Rani Therapeutics has revealed new pharmacokinetic (PK) and pharmacodynamic (PD) data from a preclinical study evaluating the oral...
FDA approves semaglutide to reduce the risk of worsening kidney disease and cardiovascular death
The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to...
Insurance coverage and type of employment shaping inequities in access to semaglutide
A study by Boston University School of Public Health (BUSPH) researchers has found that disparities in access to semaglutide, with rates...
STEP UP: Semaglutide 7.2mg achieves 20.7% weight loss and 18.7% regardless of treatment adherence
Novo Nordisk has announced headline results from the STEP UP study, a phase 3b trial in the global STEP programme, which revealed the...
Biomea Fusion announces first data on icovamenib-semaglutide combination study
Biomea Fusion has announced ‘compelling’ results from in vivo studies of icovamenib in combination with semaglutide. Icovamenib is an...
Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...
Browse by tag
bottom of page